Tag: phase
Nanobiotix announces that it has completed the dose escalation portion of the Phase 1 study evaluating NBTXR3
By Claude Leguilloux Published on 04/03/2024 at 7:22 a.m. (Boursier.com) — Nanobiotix a French biotechnology company in…
3:3 equalized in 90+8: Stuttgart saved itself for a draw in a wild final phase
3:3 equalized in 90th + 8th Stuttgart saves itself to a draw in a wild final phase March 31, 2024, 7:33 p.m Until well into stoppage time, it looked like…
WoW SoD: P3 has been announced, the Phase Raid is known – World of Warcraft Classic
While Wоіѕіе 2 of the Déсоuvеrtе was launched at the beginning of February 2024, the third year will arrive from April, Only two months later. Вlіzzаrd еffесtіvеmеnt а іndіqué ѕоn…
Merck and co inc: Failure of a phase III trial on Keytruda + Lynparza
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Nokia: 1st phase of the share buyback program – 03/18/2024 at 6:11 p.m.
Member Login Customer Login (CercleFinance.com) – In accordance with the share buyback program announced on January 25, 2024, Nokia decided today to launch the first phase of the share buyback…
Nokia: 1st phase of the share buyback program
(CercleFinance.com) – In accordance with the share buyback program announced on January 25, 2024, Nokia decided today to launch the first phase of the share buyback program. The total purchase…
Inventiva announces positive results from the proof-of-concept Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes – 03/18/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating the…
More confrontation with Israel: Houthi and Hamas plan “next phase” of war
More confrontation with Israel Houthi and Hamas plan “next phase” of war March 16, 2024, 5:16 p.m Listen to article This audio version was artificially generated. More info | Send…
Sanofi announces phase II results for Amlitelimab – 03/11/2024 at 07:08
Sanofi SA SASY.PA: * NEW PHASE II RESULTS RELATING TO AMLITELIMAB CONFIRM ITS POTENTIAL AS BEST-IN-CLASS DRUG IN TERMS OF MAINTAINING RESPONSE IN THE TREATMENT OF ATOPIC DERMATITIS *BREAKING DATA…
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved – 03/11/2024 at 07:30
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved•The presence of SENS-401 is confirmed in the…
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…